Your browser is no longer supported. Please, upgrade your browser.
Agenus Inc.
Index- P/E- EPS (ttm)-1.09 Insider Own0.20% Shs Outstand182.67M Perf Week-8.55%
Market Cap769.94M Forward P/E- EPS next Y-1.06 Insider Trans0.00% Shs Float173.55M Perf Month7.90%
Income-173.60M PEG- EPS next Q-0.22 Inst Own56.50% Short Float13.72% Perf Quarter12.82%
Sales91.40M P/S8.42 EPS this Y44.60% Inst Trans4.48% Short Ratio8.30 Perf Half Y-1.74%
Book/sh-1.09 P/B- EPS next Y0.90% ROA-95.70% Target Price- Perf Year56.52%
Cash/sh0.59 P/C6.75 EPS next 5Y- ROE82.80% 52W Range1.82 - 5.95 Perf YTD24.53%
Dividend- P/FCF- EPS past 5Y-2.30% ROI- 52W High-33.45% Beta1.68
Dividend %- Quick Ratio- Sales past 5Y84.70% Gross Margin98.30% 52W Low117.58% ATR0.31
Employees328 Current Ratio0.90 Sales Q/Q-25.60% Oper. Margin- RSI (14)41.45 Volatility4.72% 8.12%
OptionableYes Debt/Eq- EPS Q/Q15.30% Profit Margin- Rel Volume0.77 Prev Close4.00
ShortableYes LT Debt/Eq- Earnings- Payout- Avg Volume2.87M Price3.96
Recom1.30 SMA20-12.48% SMA502.36% SMA2003.58% Volume2,218,723 Change-1.00%
Nov-19-19Resumed B. Riley FBR Buy $6
Apr-22-19Initiated B. Riley FBR Buy
Oct-28-16Downgrade H.C. Wainwright Buy → Neutral $10 → $5
Oct-27-16Reiterated Maxim Group Buy
Mar-11-16Upgrade Maxim Group Hold → Buy $7
Dec-16-15Initiated Jefferies Buy
Oct-27-15Downgrade Maxim Group Buy → Hold
Jul-27-15Reiterated MLV & Co Buy $9 → $11
Jun-11-15Initiated Oppenheimer Outperform $14
Jan-12-15Reiterated Maxim Group Buy $10 → $11
Jan-09-15Reiterated MLV & Co Buy $6 → $9
Jan-09-15Reiterated Maxim Group Buy $10 → $11
Dec-19-14Reiterated Maxim Group Buy $8 → $10
May-08-14Reiterated Maxim Group Buy $17 → $11
Mar-14-14Reiterated MLV & Co Buy $9 → $11
Oct-08-13Reiterated Maxim Group Buy $19
Jan-05-12Initiated William Blair Outperform
Dec-01-11Initiated Global Hunter Securities Buy $6
Feb-09-21 05:06PM  
Feb-05-21 07:43AM  
Feb-04-21 08:30AM  
Jan-31-21 01:00AM  
Jan-26-21 08:30AM  
Jan-19-21 12:09PM  
Dec-13-20 09:44PM  
Dec-03-20 07:45AM  
Dec-01-20 08:00AM  
Nov-25-20 01:28PM  
Nov-16-20 07:04PM  
Nov-13-20 02:43PM  
Nov-12-20 09:00AM  
Nov-11-20 07:30AM  
Nov-10-20 08:45AM  
Nov-09-20 08:15AM  
Nov-05-20 08:00AM  
Nov-02-20 02:39PM  
Oct-30-20 03:30AM  
Oct-29-20 09:05AM  
Oct-22-20 12:33PM  
Oct-20-20 10:34AM  
Oct-14-20 05:00PM  
Oct-13-20 08:30AM  
Oct-01-20 07:13AM  
Sep-21-20 12:58PM  
Sep-18-20 10:13AM  
Sep-17-20 05:06PM  
Sep-11-20 10:28AM  
Sep-10-20 02:27PM  
Aug-31-20 08:00AM  
Aug-27-20 03:30PM  
Aug-26-20 02:46PM  
Aug-19-20 08:30AM  
Aug-06-20 11:55AM  
Aug-05-20 12:00PM  
Jul-21-20 01:31PM  
Jul-13-20 12:00PM  
Jul-05-20 03:40PM  
Jul-03-20 10:25AM  
Jun-26-20 12:00PM  
Jun-25-20 11:30AM  
Jun-24-20 04:53PM  
Jun-23-20 10:34AM  
Jun-22-20 09:43AM  
Jun-17-20 11:06AM  
Jun-16-20 08:12AM  
Jun-08-20 02:32PM  
Jun-06-20 11:31AM  
Jun-05-20 12:37AM  
Jun-03-20 07:39AM  
Jun-02-20 11:30AM  
Jun-01-20 09:21AM  
May-29-20 01:28PM  
May-28-20 09:42AM  
May-26-20 05:47PM  
May-14-20 11:56AM  
May-13-20 09:54AM  
May-11-20 12:00PM  
May-08-20 07:30PM  
May-07-20 09:35AM  
Apr-30-20 12:34PM  
Apr-28-20 11:50AM  
Apr-16-20 08:56AM  
Apr-07-20 01:04PM  
Apr-06-20 09:00AM  
Mar-24-20 12:00PM  
Mar-16-20 06:09AM  
Mar-13-20 11:57AM  
Mar-12-20 10:05AM  
Mar-10-20 09:14AM  
Mar-05-20 12:30PM  
Mar-03-20 08:00AM  
Feb-28-20 08:58AM  
Agenus Inc., a clinical-stage immuno-oncology company, discovers, manufactures, and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody discovery platform for the identification of fully-human and humanized monoclonal antibodies; and display technologies. It develops vaccine programs, including Prophage vaccine candidate; AutoSynVax, a synthetic neo-antigen; PhosPhoSynVax, a vaccine candidate designed to induce immunity against a class of tumor specific neo-epitopes; and QS-21 Stimulon adjuvant, a saponin-based vaccine adjuvant. The company also develops CTLA-4 and PD-1 antagonists which is in clinical trial phase I for the dose escalation study; AGEN2373, an anti-CD137 monospecific antibody which is in Phase 1 clinical trial; AGEN1223, a novel bispecific antibody designed to deplete regulatory T cells which is in a Phase 1 clinical trial; GS-1423, a tumor microenvironment conditioning anti-CD73/TGF TRAP bi-functional antibody which is in Phase 1 clinical trial; and TIGIT antibodies. In addition, it engages in the development of INCAGN1876, an anti-GITR monospecific antibody; INCAGN1949, an anti-OX40 monospecific antibody; INCAGN2390, an anti-TIM-3 monospecific antibody; INCAGN2385, an anti-LAG-3 monospecific antibody; and MK-4830, a monospecific antibody targeting ILT4. Agenus Inc. has collaboration agreements with Incyte Corporation, Merck Sharpe & Dohme, and Recepta Biopharma SA.; and collaboration with Gilead Sciences, Inc. to develop immuno-oncology therapies. The company was formerly known as Antigenics Inc. and changed its name to Agenus Inc. in January 2011. Agenus Inc. was founded in 1994 and is headquartered in Lexington, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
INCYTE CORP10% OwnerJun 17Sale3.66141,920518,83116,972,968Jun 18 05:30 PM
INCYTE CORP10% OwnerJun 16Sale3.6672,080264,00717,114,888Jun 18 05:30 PM
INCYTE CORP10% OwnerJun 15Sale3.57384,0251,372,16017,186,968Jun 15 08:47 PM
INCYTE CORP10% OwnerJun 12Sale3.589,10032,55617,570,993Jun 15 08:47 PM
INCYTE CORP10% OwnerJun 11Sale3.77183,875692,78617,580,093Jun 15 08:47 PM